CDK4 and neoplasm: These include the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor trilaciclib [107] that induces a transient and reversible arrest of hematopoietic stem and progenitor cells, thereby protecting them from the neutropenic impacts of chemotherapeutic agents that remain effective against the tumor cells [108].